2022 United States Rx-to-OTC Switches Market Report 8th Edition – Featuring GlaxoSmithKline, Perrigo Company and Prestige Brands Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The Market for Rx-to-OTC Switches, 8th Edition” report has been added to ResearchAndMarkets.com’s offering.

This report analyses recent switches, products that are near switching. It estimates markets for switched products.

More than 700 pharmaceutical products have made the switch from Rx to OTC over the past several decades. The U.S. Rx-to-OTC market has grown into a $13.8 billion market. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, the FDA willingness to work with industry, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as over-the-counter products, once available only by prescription.

Aging baby boomers, many of which are taking greater interest in their health, have created a growing Rx-to-OTC industry in America. This was reinforced by the pandemic, which presented patients with more selfcare due to lockdowns and mandates. It is anticipated that Rx-to-OTC switch products will continue to grow as interest from both consumers and developers continue to expand.

Many of the new products that are on the market may be potential candidates after standing the test of time as a prescription product. Also, the demand for OTC products is not likely to diminish, giving rise to more possibilities in the switched categories. Over one third of American consumers use an OTC medication at least every other day and the numbers are increasing on a regular basis as more products appear on the OTC market.

The current climate of patient-consumer awareness of health issues is continuing to influence the Rx-to-OTC market. Consumers are more prepared to take responsibility for their own health and are willing to purchase medicines over the counter. An increased focus on cost-savings, coupled with the effects of advertising and promotion, result in a higher rate of OTC purchases.

Companies Mentioned

• Bayer
• GlaxoSmithKline
• Johnson & Johnson
• Perrigo Company
• Prestige Brands
• Procter & Gamble
• Reckitt Benckiser
• Sanofi (Chattem)

As part of its coverage, this report contains:

• Issues and Trends Affecting The Rx-To-OTC Switches Market
• Leading Participants
• Information on the OTC industry
• Overview Of The Over-The-Counter Drug Market
• International Trends In Rx-To-OTC Switches
• Markets by Category
• Allergy, Cough, Cold, and Sinus Products: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
• Analgesics and Other Pain Relievers Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
• Anti-Infectives: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
• Gastrointestinal Drugs: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
• Smoking Cessation Products: Recent Switches, Market Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents), Conditions Information, Overview
• Other Drugs: Recent Switches, Overview, Size, Forecast, Market Share, Brand vs. Switched Brands vs. Generics (Switched Equivalents)
• Total Market: Market Size, Forecast, Market Share

Key Topics Covered:

Chapter 1: Executive Summary

Chapter 2: The OTC Drug Industry

Chapter 3: Allergy, Cough, Cold, and Sinus Products

Chapter 4: Analgesics and Other Pain Relievers

Chapter 5: Anti-Infectives

Chapter 6: Gastrointestinal Drugs

Chapter 7: Smoking Cessation Products

Chapter 8: Other Drug Classifications

Chapter 9: Total Rx-to-OTC Drug Market Summary

Chapter 10: Issues and Trends

• Naloxone Switch Encouraged by Congress
• Trends in Consumer Health Divisions
• Retail Strategies
• Mergers, Acquisitions and Partnerships
• Simultaneous Marketing – Prescription vs. OTC
• Impact on the Prescription Drug Manufacturer
• Direct-to-Consumer Advertising
• Patent Expiration
• Insurance Coverage for OTC Products

Chapter 11: Profiles for Major Rx-to-OTC Participants

For more information about this report visit https://www.researchandmarkets.com/r/3mcwmj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900